Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Seven reasons the beleaguered biotech sector is now a 'buy'
11:33am, Saturday, 18'th Jun 2022 MarketWatch
Investors ought to take advantage of low prices for a long-term view.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
12:31pm, Friday, 17'th Jun 2022 Zacks Investment Research
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
10:50am, Friday, 17'th Jun 2022
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
04:15pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
04:58pm, Wednesday, 15'th Jun 2022
Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per
3 Falling Stocks That Are Still Overpriced
02:15pm, Wednesday, 15'th Jun 2022 The Motley Fool
These are stocks you shouldn't buy on the dip.
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
11:30am, Wednesday, 15'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from clinical studies aimed at assessing remaining unmet needs for people living with spinal mu
3 Falling Stocks That Are Still Overpriced
10:15am, Wednesday, 15'th Jun 2022
These are stocks you shouldn't buy on the dip.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
05:00pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
11:30am, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is celebrating 20 years of caring deeply with the 20th anniversary of the Biogen Foundation and the Biogen Community La
Is Biogen a Bargain or a Bust?
03:15pm, Thursday, 09'th Jun 2022 The Motley Fool
Has the stock become a value trap?
7 No-Brainer Biotech Stocks to Add to Your Buy List
09:58am, Thursday, 09'th Jun 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
12:51pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disea
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
10:32am, Tuesday, 07'th Jun 2022
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disea
Why Shares of Sage Therapeutics Climbed 15.6% This Week
10:20pm, Friday, 03'rd Jun 2022 The Motley Fool
Investors can see the finish line for the company's second marketed therapy.
